Centessa Pharmaceuticals plc ADR [CNTA] stock is trading at $17.26, down -2.98%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CNTA shares have gain 5.18% over the last week, with a monthly amount glided 10.36%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Morgan Stanley upgraded its rating to Overweight on September 20, 2024, and elevated its price target to $26. On September 19, 2024, B. Riley Securities initiated with a Buy rating and assigned a price target of $33 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $14 on July 18, 2024. Jefferies upgraded its rating to a Buy and raised its price target to $11 on November 15, 2023. Morgan Stanley upgraded its rating to Equal-Weight for this stock on October 26, 2023, and upped its price target to $8. In a note dated June 21, 2023, Evercore ISI initiated an Outperform rating.
Centessa Pharmaceuticals plc ADR [CNTA] stock has fluctuated between $7.75 and $19.09 over the past year. Currently, Wall Street analysts expect the stock to reach $23.25 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $17.26 at the most recent close of the market. An investor can expect a potential return of 34.7% based on the average CNTA price forecast.
Analyzing the CNTA fundamentals
Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -23.43%, Pretax Profit Margin comes in at -22.95%, and Net Profit Margin reading is -23.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.52 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.85 points at the first support level, and at 16.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.78, and for the 2nd resistance point, it is at 18.30.
Ratios To Look Out For
For context, Centessa Pharmaceuticals plc ADR’s Current Ratio is 21.52. Further, the Quick Ratio stands at 21.52, while the Cash Ratio is 14.96. Considering the valuation of this stock, the price to sales ratio is 328.86, the price to book ratio is 4.55.
Transactions by insiders
Recent insider trading involved Anderson Karen M., Chief People Officer, that happened on Feb 07 ’25 when 30526.0 shares were sold. Chief People Officer, Anderson Karen M. completed a deal on Feb 10 ’25 to sell 429.0 shares. Meanwhile, Officer Anderson Karen M. bought 429.0 shares on Feb 10 ’25.
